Investing Profile

Kush Parmar

InvestorVC
Managing Partner at 5AM Ventures
5amventures.comBoston, Massachusetts
Photo of Kush Parmar, Managing Partner at 5am Ventures
Your Intro Paths to Kush Parmar

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Find Kush Parmar on

cb
Current Investing Position
5am Ventures Managing Partner
Investment Range
$100K - $5.0M
Sweet Spot
$1.5M
Investments On Record
17

Kush Parmar is on these Sector & Stage Rankings

Kush Parmar's Investments On Record (7)

CompanyStageDateRound SizeTotal Raised
Precede Biosciences
Series AOct 2023$57M
$57M
Ensoma
Series BJan 2023$85M
Series AFeb 2021$70M
$210M
Co-investors: Stephen Knight (F-Prime Capital Partners), Kouki Harasaki (Bioluminescence Ventures), Mark Chin (Arix Bioscience)
Vor Biopharma
Series BJul 2020$110M
Series AFeb 2019$42M
$150M
Akouos
Series BMar 2020$110M
Series AAug 2018$50M
SeedNov 2017$8M
$160M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Heather Preston
Cleave Therapeutics
Series CAug 2019$12M
Series BAug 2016$37M
Series ANov 2011$42M
$100M
Co-investors: Carol Gallagher (New Enterprise Associates (NEA)), Robert Garland (New Enterprise Associates (NEA)), Peter Thompson (OrbiMed), Andrew Schwab (5am Ventures), Marc Singer (Osage University Partners), Alfred Scheidegger (Nextech Invest), Larry Lasky (The Column Group)
Arvinas
Series CApr 2018$55M
Series BOct 2015$42M
Series ASep 2013$15M
$140M
Co-investors: Colleen Cuffaro (Canaan Partners), Stephen Squinto (OrbiMed), Tim Shannon (Canaan Partners), Martin Alexander Gershon (Endeavor Venture Funds), Liam Ratcliffe (Access Biotechnology), Daniel Wagner (Connecticut Innovations), Andrew Levin (RA Capital), Jakob Loven (Nextech Invest)
Audentes Therapeutics
Series COct 2015$65M
Series BDec 2014$43M
Series AJul 2013$30M
$140M
Co-investors: Jonathan Silverstein (OrbiMed), Stephen Squinto (OrbiMed), Jonathan Leff (Deerfield Management), Tom Woiwode (Versant Ventures)